TALS - Talaris Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5300
+0.0600 (+2.43%)
At close: 04:00PM EDT
2.5300 0.00 (0.00%)
After hours: 04:01PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Head and Shoulders Top

Head and Shoulders Top

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.4700
Open2.5000
Bid2.5200 x 3000
Ask2.5400 x 800
Day's Range2.4200 - 2.5700
52 Week Range0.8900 - 8.6000
Volume413,410
Avg. Volume288,568
Market Cap109.589M
Beta (5Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-1.8100
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TALS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Talaris Therapeutics Announces Leadership Transition

    BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. “On behalf of the board, I would like to tha

  • Simply Wall St.

    Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30%

    Key Insights Talaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...

  • American City Business Journals

    Wellesley biotech cuts one-third of staff, explores sale

    A biotech with joint operations in Wellesley, Massachusetts and Louisville, Kentucky is laying off about one-third of its staff as it culls two drug programs.

  • GlobeNewswire

    Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

    BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical

  • Simply Wall St.

    We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

    BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2

  • GlobeNewswire

    Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

    Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ trans

  • GlobeNewswire

    Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

    BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting. The first presentation reported o

  • Zacks

    Talaris (TALS) Down on Patient Death From Renal Transplant Study

    Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

  • Benzinga

    HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space

    HC Wainwright initiated coverage on Talaris Therapeutics Inc (NASDAQ: TALS) with a Buy rating and a price target of $18. Talaris leverages its novel “facilitated” allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform for solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders. The facilitated Allo-HSCT attempts to unify two immune systems into one (chimerism) such that both the donor and recipient immune cells function harmoniously in

  • Benzinga

    Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease

    Talaris Therapeutics Inc (NASDAQ: TALS) received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee (DMC). After their review, the DMC determined that trial enrollment and dosing may continue. The company has reported this event and the DMC's recommendation to the FDA. Related: Talaris Therapeutics Reveals COVID-19 Outcomes Among Kidney Transplant Patients Treated With FCR001. As reported, the decease

  • GlobeNewswire

    Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

    BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients. On October 18, 2022, the Company received a report of a patient death, which triggered a pre

  • GlobeNewswire

    Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

    BOSTON and LOUISVILLE, Ky., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla. Talaris will present data on the makeup of patients’ pe

  • GlobeNewswire

    Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

    BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globall

  • GlobeNewswire

    Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

    BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September

  • GlobeNewswire

    Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

    BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences: Morgan Stanley 20th Annual Global Healthcare ConferenceFireside chat date: Monday, September

  • GlobeNewswire

    Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

    All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTO

  • Simply Wall St.

    We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

    Figure 1 HLA Mismatch of FREEDOM-1 Subjects (n=7) Figure 2 Time since kidney transplant All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today at 8:00 a.m. ET B